Loading...
•
Mar 31
Aquestive Q1 2025 Earnings Report
Aquestive reported lower revenues and a wider net loss in Q1 2025, as the company shifted focus toward its Anaphylm launch preparation.
Key Takeaways
Aquestive Therapeutics generated $8.7 million in revenue for Q1 2025, down 28% year-over-year, due to declines in manufacturing and license revenues. The company intensified its commercial readiness efforts for Anaphylm and reduced non-core development activities.
Revenue fell to $8.7 million in Q1 2025 from $12.1 million a year earlier, driven by lower manufacturing and licensing income.
Net loss widened to $22.9 million, up from $12.8 million in Q1 2024, mainly due to increased SG&A expenses.
Non-GAAP adjusted EBITDA loss reached $17.6 million, compared to $7.2 million last year.
Cash and cash equivalents stood at $68.7 million at the end of Q1 2025, with the company reaffirming its launch plans for Anaphylm in early 2026.
Aquestive
Aquestive
Aquestive Revenue by Segment
Revenue by Segment
Manufacture and Supply Revenue
CapyFin.com Forward Guidance
Aquestive revised its full-year 2025 guidance downward due to Libervant's regulatory delay and reallocation of resources toward Anaphylm.
Positive Outlook
- NDA for Anaphylm submitted; FDA acceptance decision expected Q2 2025.
- Commercial launch of Anaphylm planned for Q1 2026, subject to approval.
- Expanded market access and medical affairs teams in place.
- Strong demand continued for Libervant among 2–5-year-olds despite pause in broader sales.
- Cash reserves of $68.7M support near-term operations and launch prep.
Challenges Ahead
- Total revenue guidance lowered from $47–56M to $44–50M.
- Paused marketing of Libervant following change in regulatory approval status.
- Net loss and SG&A expenses significantly increased YoY.
- Adjusted EBITDA loss widened materially versus Q1 2024.
- Plans to delay AQST-108 clinical development until post-Anaphylm launch.